Market closed
GlycoMimetics/GLYC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GlycoMimetics
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Ticker
GLYC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
35
Website
GlycoMimetics Metrics
BasicAdvanced
$11M
Market cap
-
P/E ratio
-$0.61
EPS
2.18
Beta
-
Dividend rate
Price and volume
Market cap
$11M
Beta
2.18
52-week high
$3.53
52-week low
$0.16
Average daily volume
1.1M
Financial strength
Current ratio
5.477
Quick ratio
5.156
Total debt to equity
2.237
Management effectiveness
Return on assets (TTM)
-59.25%
Return on equity (TTM)
-104.49%
Valuation
Price to revenue (TTM)
1,096.774
Price to book
0.55
Price to tangible book (TTM)
0.55
Price to free cash flow (TTM)
-0.307
Growth
Earnings per share change (TTM)
-6.62%
3-year revenue growth (CAGR)
-83.48%
3-year earnings per share growth (CAGR)
-19.78%
What the Analysts think about GlycoMimetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for GlycoMimetics stock.
GlycoMimetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GlycoMimetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for GlycoMimetics stock?
GlycoMimetics (GLYC) has a market cap of $11M as of September 16, 2024.
What is the P/E ratio for GlycoMimetics stock?
The price to earnings (P/E) ratio for GlycoMimetics (GLYC) stock is 0 as of September 16, 2024.
Does GlycoMimetics stock pay dividends?
No, GlycoMimetics (GLYC) stock does not pay dividends to its shareholders as of September 16, 2024.
When is the next GlycoMimetics dividend payment date?
GlycoMimetics (GLYC) stock does not pay dividends to its shareholders.
What is the beta indicator for GlycoMimetics?
GlycoMimetics (GLYC) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.